bluebird bio, Inc. (NASDAQ:BLUE) Given Consensus Recommendation of “Hold” by Analysts

Shares of bluebird bio, Inc. (NASDAQ:BLUE) have received a consensus rating of “Hold” from the eight brokerages that are presently covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $44.60.

Several research firms have recently weighed in on BLUE. Barclays decreased their price target on shares of bluebird bio from $40.00 to $8.00 and set an “overweight” rating on the stock in a report on Monday, March 31st. Wall Street Zen started coverage on shares of bluebird bio in a report on Thursday, May 15th. They issued a “sell” rating on the stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Groupe la Francaise purchased a new position in bluebird bio in the first quarter worth $679,000. Goldman Sachs Group Inc. boosted its position in bluebird bio by 4.7% during the first quarter. Goldman Sachs Group Inc. now owns 64,950 shares of the biotechnology company’s stock valued at $317,000 after buying an additional 2,932 shares during the period. Murchinson Ltd. purchased a new stake in bluebird bio during the first quarter valued at about $254,000. Bank of New York Mellon Corp boosted its position in bluebird bio by 12.7% during the first quarter. Bank of New York Mellon Corp now owns 32,759 shares of the biotechnology company’s stock valued at $160,000 after buying an additional 3,686 shares during the period. Finally, Regeneron Pharmaceuticals Inc. purchased a new stake in bluebird bio during the fourth quarter valued at about $175,000. 87.43% of the stock is currently owned by hedge funds and other institutional investors.

bluebird bio Stock Performance

bluebird bio stock opened at $4.97 on Friday. The stock has a market cap of $48.67 million, a P/E ratio of -0.13 and a beta of 0.27. bluebird bio has a fifty-two week low of $3.20 and a fifty-two week high of $28.60. The firm’s fifty day moving average price is $4.69 and its 200-day moving average price is $5.55. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.33 and a current ratio of 0.51.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.